Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

The top four growth drivers — Vabysmo, Phesgo, Ocrevus and Hemlibra — achieved total sales of CHF 16.9 billion, reflecting an increase of CHF 3.3 billion from that recorded in 2023.

The directors of the Irish arm of pharma giant Roche have stated that there is a need to reduce the lengthy timelines to ...

U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

and the haemophilia treatment Hemlibra (emicizumab-kxwh). Combined, these products pulled in CHF 16.9bn ($18.6bn), marking a CHF 3.3bn ($3.6bn) increase over 2023. Vabsymo, launched in early 2022 ...

Overseas sales rose for hemophilia drug Hemlibra through Swiss parent Roche. The drugmaker had forecast a drop in revenue from 2023, when it received a boost from supplying COVID-19 treatment ...

Hemlibra patient share in the U.S./EU now reaching 42%, and we are now also looking forward to the Phase III enabling readout of NXT007, which is the next-generation Hemlibra. In neurology ...